NEJM - Evolocumab in Reducing Lipids and CV Events

"Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events"

"CONCLUSIONS

During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis. (Funded by Amgen; OSLER-1 and OSLER-2 ClinicalTrials.gov numbers, NCT01439880 and NCT01854918.)"

http://www.nejm.org/doi/full/10.1056/NEJMoa1500858